Journal article
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial
- Abstract:
-
Background The ICON8 study reported no significant improvement in progression-free survival (a primary endpoint) with weekly chemotherapy compared with standard 3-weekly treatment among patients with epithelial ovarian cancer. All ICON8 patients were eligible to take part in the accompanying health-related quality-of-life study, which measured the effect of treatment on self-reported wellbeing, reported here.
Methods In this open-label, randomi...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 777.0KB, Terms of use)
-
(Preview, Supplementary materials, Version of record, pdf, 466.5KB, Terms of use)
-
- Publisher copy:
- 10.1016/S1470-2045(20)30218-7
Authors
- Publisher:
- Elsevier
- Journal:
- Lancet Oncology More from this journal
- Volume:
- 21
- Issue:
- 7
- Pages:
- 969-977
- Publication date:
- 2020-06-29
- Acceptance date:
- 2020-03-31
- DOI:
- EISSN:
-
1474-5488
- ISSN:
-
1470-2045
- Language:
-
English
- Keywords:
- Pubs id:
-
1097982
- Local pid:
-
pubs:1097982
- Deposit date:
-
2020-04-01
- ARK identifier:
Terms of use
- Copyright holder:
- Blagden et al.
- Copyright date:
- 2020
- Rights statement:
- Copyright © 2020 The Authors. Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record